Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add filters

Database
Language
Document Type
Year range
1.
Curr Diabetes Rev ; 2022 08 22.
Article in English | MEDLINE | ID: covidwho-2318627

ABSTRACT

BACKGROUND AND AIM: The present study aimed to evaluate the anxiety, depression, and fear in people with and without diabetes during the transmission of the SARS-CoV-2 Omicron variant. METHODS: In this comparative study (n=353), people with diabetes (n=121) and those without diabetes (n=232) were investigated for physiological aspects of COVID-19 during the SARS-CoV-2 Omicron variant outbreak. This study was performed at the Prince Sultan Military Medical City (PSMMC), Riyadh, Saudi Arabia. On request, the participants responded to the survey questionnaires, providing data on demographics, Generalized Anxiety Disorder (GAD-7), and Patient Health Questionnaire-2 (PHQ-2) to screen for anxiety, depression, and COVID-19-related fears. RESULTS: The GAD statement revealed a significantly higher degree of nervousness and anxiety among people with diabetes when compared to people without diabetes (P = 0.001). For the other GAD statements, no statistical difference was observed between the responses of people with and without diabetes, including the overall GAD-7 (P = 0.091). Moreover, no significant change was observed in the total GAD between those with diabetes and those without it. The PHQ-2 statement, concerning a feeling of depression or hopelessness noted a significant escalation among diabetes compared to nondiabetes (P = 0.004). Furthermore, in the overall PHQ-2, a significant escalation (P = 0.011) was noticed among people with diabetes compared to nondiabetes. In addition, people with diabetes had a significantly high (P = 0.037) COVID-19-related fear reported, compared to people without diabetes. CONCLUSION: The need for comprehensive research is urgent, as it will facilitate a better understanding of the physiological aspects of COVID-19 for patients with diabetes.

2.
Diabetes Metab Syndr ; 15(5): 102231, 2021.
Article in English | MEDLINE | ID: covidwho-1333363

ABSTRACT

BACKGROUND AND AIM: This review aims to report the current status of COVID-19 among people with diabetes, newly diagnosed diabetes, diabetic ketoacidosis, and programmatic efforts including vaccinations. METHODS: We conducted a literature search using PubMed, Google, and Scopus until July 15, 2021. RESULTS: In Saudi Arabia, most studies have reported diabetes as one of the highly prevalent comorbidities among patients with COVID-19. Currently, there are limited studies from Saudi Arabia on the newly diagnosed diabetes and diabetic ketoacidosis caused by COVID-19. The Saudi ministry has taken several measures to control the impact of COVID-19 among people with diabetes, including comprehensive guidelines and prioritized vaccinations. During the COVID-19 pandemic, the use of telehealth services dramatically increased in diabetes clinics in Saudi Arabia. CONCLUSIONS: Focused and evidence-based interventions are essential to control the impact of COVID-19 among people with diabetes.


Subject(s)
COVID-19/epidemiology , Diabetes Complications/epidemiology , COVID-19/complications , COVID-19/prevention & control , COVID-19 Vaccines/therapeutic use , Diabetes Complications/complications , Diabetes Mellitus/epidemiology , Diabetic Ketoacidosis/complications , Diabetic Ketoacidosis/epidemiology , Humans , Pandemics , SARS-CoV-2/physiology , Saudi Arabia/epidemiology , Vaccination/statistics & numerical data
3.
Curr Diabetes Rev ; 17(6): e111020187810, 2021.
Article in English | MEDLINE | ID: covidwho-921112

ABSTRACT

Coronavirus disease 2019 (COVID-19) and diabetes have major impacts on the health of the population across the world. Since the beginning of the COVID-19 pandemic, people with diabetes have been identified to be more vulnerable to infection and at greater risk for hospitalization. As diabetes is one of the major health issues in Saudi Arabia, the current study describes the perspectives of COVID-19 in people with diabetes and the steps taken by the government to minimize its impact. Most patients with COVID-19 in Saudi Arabia experience mild illness, while people with diabetes are at increased risk of disease severity and mortality. The government of Saudi Arabia has taken several measures to control and mitigate the effect of the pandemic, as the Saudi population is gradually returning back to normal life. However, currently, there are limited studies from Saudi Arabia on COVID-19 among people with diabetes and the effectiveness of interventions. We emphasize the necessity for comprehensive research, which would provide a better understanding of the incidence of COVID-19 and its association with diabetes to develop evidence- based programs and policies in the country.


Subject(s)
COVID-19 , Diabetes Mellitus , Diabetes Mellitus/epidemiology , Humans , Pandemics , SARS-CoV-2 , Saudi Arabia/epidemiology
4.
Curr Diabetes Rev ; 17(5): e211020187087, 2021.
Article in English | MEDLINE | ID: covidwho-890258

ABSTRACT

It is evident that COVID-19 and diabetes have a significant influence on population health across the world, including the Middle East and North Africa (MENA) region. COVID-19 patients with diabetes have been observed to be more prone to developing severe infections and higher risk of mortality compared to non-diabetics. As diabetes is one of the major health issues, widely prevalent in the MENA countries, the current review focused on understanding the epidemiology of COVID-19 in people with diabetes, and the interventions implemented by the governments to minimize the impact of it. Considering the importance and need, the MENA countries have enforced several prevention and control measures to mitigate the impact of the pandemic. Though there has been a considerable amount of research on COVID-19, only a few countries from the MENA region focused on the epidemiology of COVID-19 among patients with diabetes and its effects. Hence, we emphasize the need for intensive research which is an urgent need to have a clear understanding of COVID-19 and its association with diabetes to develop and implement evidence- based programs and policies in the MENA region.


Subject(s)
COVID-19 , Diabetes Mellitus , Africa, Northern/epidemiology , Diabetes Mellitus/epidemiology , Humans , Middle East/epidemiology , Public Health , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL